Why the study?
What is the incidence of residual neuromuscular blockade in patients arriving in the recovery room after receiving competitive neuromuscular blocking agents?
What is the incidence of residual neuromuscular blockade in patients arriving in the recovery room after receiving competitive neuromuscular blocking agents?
A significant proportion of patients arrive in the recovery room with residual neuromuscular blockade that is not reliably detected by clinical bedside tests.
Answers are grounded in this paper and cite their sources.
Bedside tests may miss residual neuromuscular blockade in recovery; leaves open whether quantitative monitoring should be routine.
One hundred patients who received a competitive neuromuscular blocking agent during anaesthesia were randomly selected for evaluation of neuromuscular function immediately on their arrival in the recovery room. The anaesthetist was not aware that the patient would be evaluated in the recovery room. Neuromuscular function was assessed by a train-of-four (TOF) ratio, and in conscious and co-operative patients by a series of bedside tests of neuromuscular function. Twenty-one patients had a TOF ratio of less than 0.70 and seven patients a TOF ratio of less than 0.60. Bedside tests of neuromuscular function did not reliably detect this defect in neuromuscular transmission. It is concluded that a relatively large number of patients have a defect in neuromuscular transmission on their arrival in the recovery room, and suggested that this reflects the inadequacy of clinical methods used for the administration and antagonism of competitive neuromuscular blocking agents at this institution.
No takes yet. Share an insight, caveat, or question.
Beemer et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: